drugset / Trial / NCT02649972
Single-agent Cobimetinib for Adults With Histiocytic Disorders
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects, good or bad, Cobimetinib has in patients with histiocytosis. Cobimetinib is an investigational oral medication that blocks MEK1.
Timeline
- Start
- 2016-01
- Primary completion
- 2022-12-16
- Completion
- 2022-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobimetinib | Small molecule | 60 mg | Oral |